Step Pharma is developing novel therapeutics that inhibit the enzyme CTP Synthase 1 (CTPS1). Our most advanced programme is STP938 which is being developed as a targeted therapy for T-cell malignancies.
Step Pharma was created on the basis of research on genetic immunodeficiencies led by Prof. Alain Fischer at the Imagine Institute (Paris, France) which established the essential role of CTPS1 in T- and B-cell proliferation.
...
Step Pharma is developing novel therapeutics that inhibit the enzyme CTP Synthase 1 (CTPS1). Our most advanced programme is STP938 which is being developed as a targeted therapy for T-cell malignancies.
Step Pharma was created on the basis of research on genetic immunodeficiencies led by Prof. Alain Fischer at the Imagine Institute (Paris, France) which established the essential role of CTPS1 in T- and B-cell proliferation.
Step Pharma has developed a series of potent, selective, orally available small molecular weight inhibitors of CTPS1 with STP938 expected to enter clinical development in 2022. The role of CTPS1 in modulating lymphocytes
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.